A Phase II Safety Trial of Nivolumab in Patients With Metastatic Renal Cell Carcinoma Who Have Progresses During or After Prior Systemic Anti-angiogenic Regimen

Trial Profile

A Phase II Safety Trial of Nivolumab in Patients With Metastatic Renal Cell Carcinoma Who Have Progresses During or After Prior Systemic Anti-angiogenic Regimen

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 10 Feb 2018

At a glance

  • Drugs Nivolumab (Primary)
  • Indications Renal cell carcinoma
  • Focus Adverse reactions
  • Acronyms NIVOREN
  • Sponsors UNICANCER
  • Most Recent Events

    • 10 Feb 2018 Status changed to active, no longer recruiting as per results presented at the 2018 Genitourinary Cancers Symposium
    • 10 Feb 2018 Results (n=528, data cut off: Jun 2017) presented at the 2018 Genitourinary Cancers Symposium
    • 06 Jun 2017 Preliminary results (n=588, data cut off: Dec 2016) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top